Influenza virus B infections - Pipeline Insight, 2024

This “Influenza virus B infections- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Influenza virus B infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Influenza virus B infections: Understanding

Influenza virus B infections: Overview

Influenza B virus (IBV) was isolated in 1940 for the first time and belongs to Influenza virus B genus. IBVs can also cause epidemics worldwide; however, less attention is given to IBVs compared to IAVs. The potency of IBVs appears to be increasing, and they may even lead to a higher mortality rate in comparison with IAVs in specific populations, such as HIV patients. The importance of IBVs should not be underestimated since they cause high morbidity and mortality. Influenza B tends to cause a milder form of the flu than influenza A. Influenza B typically affects children more often than adults. It generally causes stronger symptoms than influenza C. In many people, the flu goes away on its own without treatment. However, older adults and people with certain underlying health conditions may have a risk of developing serious complications. Such complications include: ear or sinus infections, pneumonia and bronchitis. Signs and symptoms of influenza in mild cases include a cough, fever, sore throat, myalgia, headache, runny nose, and congested eyes. A frontal or retro-orbital headache is a common presentation with selected ocular symptoms that include photophobia and pain with different qualities. The cause of ocular pain is related to the viral tropism that is associated with certain types and subtypes. Severe cases may progress to shortness of breath, tachycardia, hypotension, and need for supportive respiratory interventions in as little as 48 hours. Diagnosis of influenza can be reached clinically, especially during the influenza season. Most of the cases will recover without medical treatment, and they would not need a laboratory test for the diagnosis. In high-risk cases, initiation of treatment should not be delayed until test results are obtained. Influenza laboratory tests should be ordered for cases where testing would inform clinical action or public health interventions such as the outbreak situations where the diagnosis of the causative agent is necessary for therapeutic and prophylactic recommendations. Influenza infection is self-limited and mild in most healthy individuals who do not have other comorbidities. No antiviral treatment is needed during mild infections in healthy individuals. Antiviral medications can be used to treat or prevent influenza infection, especially during outbreaks in healthcare settings such as hospitals and residential institutions.

Influenza virus B infections- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Influenza virus B infections pipeline landscape is provided which includes the disease overview and Influenza virus B infections treatment guidelines. The assessment part of the report embraces, in depth Influenza virus B infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Influenza virus B infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Influenza virus B infections R&D. The therapies under development are focused on novel approaches to treat/improve Influenza virus B infections.

Influenza virus B infections Emerging Drugs Chapters

This segment of the Influenza virus B infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Influenza virus B infections Emerging Drugs

CR 9114 : Leyden LabsIn January 2022, Leyden Labs announced that the company has an exclusive license to develop and commercialize CR9114, a pan-influenza antibody protecting against influenza A and B.Leyden Labs are working hard to develop PanFlu product candidate and advance it into the clinic.

SAB 176 : SAB Biotherapeutics SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate that leverages the human biological immune response in development for the treatment of hospitalized patients with severe seasonal influenza. The novel specifically targeted therapeutic generated from the company’s proprietary technology, the DiversitAb platform, is designed to specifically bind to Type A and Type B influenza viruses. Pre-clinical data suggests that SAB-176 offers potentially broad protection against diverse influenza strains. A highly-potent, polyclonal antibody therapy for severe seasonal influenza, could potentially treat severely ill patients and provide protective antibodies for high-risk populations, such as the elderly and immunecompromised.

Influenza virus B infections: Therapeutic Assessment

This segment of the report provides insights about the different Influenza virus B infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Influenza virus B infections

There are approx. 10+ key companies which are developing the therapies for Influenza virus B infections. The companies which have their Influenza virus B infections drug candidates in the most advanced stage, i.e. phase I include, SAB Biotherapeutics.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Influenza virus B infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Influenza virus B infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Influenza virus B infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Influenza virus B infections drugs.

Influenza virus B infections Report Insights

• Influenza virus B infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Influenza virus B infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Influenza virus B infections drugs?
• How many Influenza virus B infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Influenza virus B infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Influenza virus B infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Influenza virus B infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Leyden Labs
• Nanjing Zenshine Pharmaceuticals
• SAB Biotherapeutics

Key Products

• CR 9114
• ZX 7101A
• SAB 176

This product will be delivered within 1-3 business days.